Tyrosine kinase inhibitors in HER2-positive metastatic breast cancer with trastuzumab emtansine resistance: insights from a multicenter retrospective real-world study

Abstract

The use of trastuzumab emtansine (T-DM1) has revealed significant efficacy in HER2-positive metastatic breast cancer (MBC). However, optimal therapeutic strategies following T-DM1 failure remain a subject of debate in clinical practice. In this multicenter, retrospective, real-world study, we sought to examine the effectiveness and safety of tyrosine kinase inhibitors (TKIs) as a therapeutic strategy in HER2-positive MBC who developed T-DM1 resistance. Between September 2018 and December 2022, 66 patients were enrolled. The median progression-free survival of TKIs-based therapy was 10.1 months (95% CI, 4.7–15.6). Objective response rate and clinical benefit rate were 18.2 and 66.7%, respectively. TKIs-based therapy demonstrated better effectiveness in patients who had previously derived benefit from T-DM1 and featured acquired resistance to trastuzumab. The most common adverse events were diarrhea (36, 54.5%), hand-foot syndrome (31, 47.0%), and leucopenia (30, 45.5%). In conclusion, TKIs-based therapy showed promising effectiveness and safety in HER2-positive MBC patients after T-DM1 failure.

Keywords

HER2-positive breast cancer / real-world study / trastuzumab emtansine resistance / tyrosine kinase inhibitors

References

1	AN Giaquinto, H Sung, KD Miller, et al. Breast Cancer Statistics, 2022. CA Cancer J Clin. 2022;72(6):524-541. doi:
2	Y Feng, M Spezia, S Huang, et al. Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018;5(2):77-106. doi:
3	S Sjogren, M Inganas, A Lindgren, L Holmberg, J Bergh. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol. 1998;16(2):462-469. doi:
4	A Marra, S Chandarlapaty, S Modi. Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives. Nat Rev Clin Oncol. 2024. doi:
5	F Cardoso, S Paluch-Shimon, E Senkus, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623-1649. doi:
6	SM Swain, SB Kim, J Cortes, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14(6):461-471. doi:
7	S Verma, D Miles, L Gianni, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783-1791. doi:
8	G von Minckwitz, CS Huang, MS Mano, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617-628. doi:
9	WJ Gradishar, MS Moran, J Abraham, et al. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(6):691-722. doi:
10	N Harbeck, F Penault-Llorca, J Cortes, et al. Breast cancer. Nat Rev Dis Primers. 2019;5(1):66. doi:
11	HS Rugo, SA Im, F Cardoso, et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2021;7(4):573-584. doi:
12	C Saura, M Oliveira, YH Feng, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with >/= 2 HER2-directed regimens: phase III NALA trial. J Clin Oncol. 2020;38(27):3138-3149. doi:
13	G Curigliano, V Mueller, V Borges, et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol. 2022;33(3):321-329. doi:
14	S Modi, C Saura, T Yamashita, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610-621. doi:
15	Z Jiang, J Li, J Chen, et al. Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2022. Transl Breast Cancer Res. 2022;3.
16	CE Geyer, J Forster, D Lindquist, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733-2743. doi:
17	L Baez-Vallecillo, AS Raghavendra, KR Hess, et al. Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1). Breast Cancer Res Treat. 2019;176(1):227-234. doi:
18	EM Olson, NU Lin, PJ DiPiro, et al. Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. Ann Oncol. 2012;23(1):93-97. doi:
19	B Xu, M Yan, F Ma, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(3):351-360. doi:
20	M Yan, L Bian, X Hu, et al. Pyrotinib plus capecitabine for human epidermal factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study. Transl Breast Cancer Res. 2020;1.
21	GM Choong, GD Cullen, CC O'Sullivan. Evolving standards of care and new challenges in the management of HER2-positive breast cancer. CA Cancer J Clin. 2020;70(5):355-374. doi:
22	M Anwar, Q Chen, D Ouyang, et al. Pyrotinib treatment in patients with HER2-positive metastatic breast cancer and brain metastasis: exploratory final analysis of real-world, multicenter data. Clin Cancer Res. 2021;27(16):4634-4641. doi:
23	Y Li, C Gong, Q Lu, et al. Real-world data of triplet combination of trastuzumab, lapatinib, and chemotherapy in HER2-positive metastatic breast cancer: a multicenter retrospective study. Front Oncol. 2020;10:271. doi:
24	W Wang, H He, NI Marin-Ramos, et al. Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer. Neuro Oncol. 2021;23(10):1656-1667. doi:
25	T Bachelot, G Romieu, M Campone, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14(1):64-71. doi:
26	M Yan, Q Ouyang, T Sun, et al. Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial. Lancet Oncol. 2022;23(3):353-361. doi:
27	M Gao, C Fu, S Li, et al. The efficacy and safety of pyrotinib in treating HER2-positive breast cancer patients with brain metastasis: a multicenter study. Cancer Med. 2022;11(3):735-742. doi:
28	C Saura, J Matito, M Oliveira, et al. Biomarker analysis of the phase III NALA study of neratinib + capecitabine versus lapatinib + capecitabine in patients with previously treated metastatic breast cancer. Clin Cancer Res. 2021;27(21):5818-5827. doi:
29	A Chan, S Delaloge, FA Holmes, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(3):367-377. doi:
30	Y Li, Z Tong, X Wu, et al. Real-world treatment patterns and outcomes of pyrotinib-based therapy in patients with HER2-positive advanced breast cancer (PRETTY): a nationwide, prospective, observational study. Int J Cancer. 2023;153(10):1809-1818. doi:
31	G Arpino, L Wiechmann, CK Osborne, R Schiff. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev. 2008;29(2):217-233. doi:
32	L Zhang, X Wu, J Zhou, et al. Pyrotinib in the treatment of women with HER2-positive advanced breast cancer: a multicenter, prospective, real-world study. Front Oncol. 2021;11:699323. doi:
33	MA Barbieri, EE Sorbara, G Cicala, et al. Adverse drug reactions with HER2-positive breast cancer treatment: an analysis from the Italian Pharmacovigilance Database. Drugs Real World Outcomes. 2022;9(1):91-107. doi:
34	F Ma, Q Li, S Chen, et al. Phase I study and biomarker analysis of pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2017;35(27):3105-3112. doi:
35	H Uppal, E Doudement, K Mahapatra, et al. Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1). Clin Cancer Res. 2015;21(1):123-133. doi:
36	H Wong, R Leung, A Kwong, et al. Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2(+) metastatic breast cancer. Oncologist. 2011;16(11):1535-1546. doi:
37	KS Saini, C Twelves. Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework. Br J Cancer. 2021;125(2):155-163. doi: